SCHEMBL21151780

SCHEMBL21151780

O=C(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn1cc(-c2ccc(NC(=O)C3CC(=O)N(c4ccccc4)C3)cc2)nn1)ON1C(=O)CCC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 2/20 0.45
▸ ROCK1 Q13464 2/20 0.45
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA4 P22748 1/20 0.44
▸ CA6 P23280 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA13 Q8N1Q1 1/20 0.44
▸ CA5B Q9Y2D0 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ GAA P10253 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24974601 0.81 ROCK2 (0.54) ROCK2ROCK1CA12CA1CA2
SCHEMBL18373050 0.77 SRC (0.47) MEN1KMT2A
SCHEMBL24974782 0.75 MAPT (0.58) MAPTALDH1A1GAATSHRPOLB
SCHEMBL24974742 0.74 MAPT (0.58) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL24974600 0.74 GBA1 (0.50) CA12CA1CA2CA9
SCHEMBL24974744 0.72 NAMPT (0.43) ALDH1A1GAANAMPT
SCHEMBL19522200 0.71 SRC (0.43) MEN1KMT2A
SCHEMBL18356613 0.71 NAMPT (0.37) NAMPT
SCHEMBL24974634 0.71 POLB (0.56) MAPTALDH1A1POLB
SCHEMBL20798413 0.69 HDAC3 (0.60) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 — — US disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B ROCK2 1950/4885ROCK1 1772/4885CA12 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback